Analyst Price Targets — TENX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 17, 2025 11:50 am | — | Guggenheim | $25.00 | $11.16 | TheFly | Tenax Therapeutics price target raised to $25 from $14 at Guggenheim |
| September 8, 2025 8:53 am | Yasmeen Rahimi | Piper Sandler | $20.00 | $6.04 | TheFly | Tenax Therapeutics initiated with an Overweight at Piper Sandler |
| May 15, 2025 1:20 pm | Seamus Fernandez | Guggenheim | $15.00 | $5.70 | TheFly | Tenax Therapeutics price target lowered to $15 from $16 at Guggenheim |
| March 10, 2025 10:22 am | — | Leerink Partners | $20.00 | $6.19 | StreetInsider | Tenax Therapeutics (TENX) PT Raised to $20 at Leerink PartnersMember Login |
Latest News for TENX
Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience
Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R.
Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $10.78 and traded as high as $16.95. Tenax Therapeutics shares last traded at $16.00, with a volume of 557,161 shares trading hands. Analyst Upgrades
Shares of Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $10.43 and traded as high as $14.24. Tenax Therapeutics shares last traded at $13.23, with a volume of 354,937 shares traded. Analysts Set New Price Targets
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TENX.
U.S. House Trading
No House trades found for TENX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.